NasdaqGS - Delayed Quote USD
Beam Therapeutics Inc. (BEAM)
27.62 -1.67 (-5.70%)
At close: January 30 at 4:00:03 PM EST
27.80 +0.18 (+0.65%)
After hours: January 30 at 7:59:55 PM EST
Chart Range Bar
Loading chart for BEAM
- Previous Close
29.29 - Open
29.00 - Bid 20.88 x 200
- Ask 35.23 x 200
- Day's Range
27.44 - 29.04 - 52 Week Range
13.52 - 36.44 - Volume
1,293,025 - Avg. Volume
1,975,606 - Market Cap (intraday)
2.803B - Beta (5Y Monthly) 2.07
- PE Ratio (TTM)
-- - EPS (TTM)
-4.41 - Earnings Date Nov 4, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
47.21
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease; BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. It also intends to develop BEAM-103, an anti-CD117 monoclonal antibody, and BEAM-104, a cell therapy for development in sickle cell disease and beta-thalassemia; and BEAM-201 and other potential ex vivo CAR-T therapies. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
beamtx.comRecent News: BEAM
View More
Performance Overview: BEAM
Trailing total returns as of 1/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
BEAM
0.36%
S&P 500 (^GSPC)
1.37%
1-Year Return
BEAM
1.25%
S&P 500 (^GSPC)
14.29%
3-Year Return
BEAM
34.39%
S&P 500 (^GSPC)
72.71%
5-Year Return
BEAM
71.36%
S&P 500 (^GSPC)
86.82%
Earnings Trends: BEAM
View MoreAnalyst Insights: BEAM
View MoreStatistics: BEAM
View MoreValuation Measures
As of 1/29/2026
Market Cap
2.97B
Enterprise Value
2.05B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
46.55
Price/Book (mrq)
2.90
Enterprise Value/Revenue
33.74
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-23.48%
Return on Equity (ttm)
-47.19%
Revenue (ttm)
55.7M
Net Income Avi to Common (ttm)
-414.64M
Diluted EPS (ttm)
-4.41
Balance Sheet and Cash Flow
Total Cash (mrq)
1.07B
Total Debt/Equity (mrq)
15.68%
Levered Free Cash Flow (ttm)
-166.76M
Compare To: BEAM
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Company Insights: BEAM
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected. Learn more
Dividend Score
The distribution of earnings a company pays back to its shareholders based off the company’s profits. Usually paid out on a quarterly basis in the form of cash or additional stocks.
Hiring Score
A company’s hiring trends in key indicators can indicate how well the company is doing in terms of growing the company and where they are currently prioritizing.
Insider Sentiment Score
Vicker’s Insider Sentiment provides insights into trades made by insiders. This can be used to gain valuable insights and as a reflection of the prospect of the company based on insider trading.